BiotechTV - News

He sees an optimistic turn after a challenging couple of years. Plus, highlighting Vicor, Camurus, Oculis, and BioArctic.

CEO Thomas Feldthus describes the challenge of making ion channel medicines selective enough to avoid unwanted side effects. He walks us through the Jazz and Acadia partnership, and highlights three other internally developed programs.

She describes the transferrin receptor based brain transporter technology, which the company recently signed another new partner (Novartis) on for $30M up front. Plus, the European approval of Leqembi, and how the Parkinson's program is progressing.

He describes the science behind the A1M protein that this is based on, and how Guard has chosen kidney protection for patients who are undergoing heart surgery as the lead indication. We walk through various scenarios ahead of the upcoming readout.

CEO Martin Welschof walks us through these two programs, which both target liquid and solid tumors. BI-1808 recently had data at EHA and will have solid tumor data later this year, while 2026 will be data rich for BI-1206.

CEO David Veitch walks us through the U.S. launch of Zevtera, and discusses where Cresemba is in its global commercial lifecycle. Plus, pipeline progress, and how Basilea's experience with BARDA funding has been a good sign of consistency for the field.

Christophe Weber discusses the 25 year journey from the discovery that orexin deficiency is the cause of narcolepsy to announcing two positive phase three studies with an agonist. He shares highlights of the World Sleep Congress data, and how he views emerging competitors in the class.

Founding Partner Stephen Thompson and Partner Jonathan Tobin list some of their recent investments, highlight the advantage of running speedy clinical trials in Australia, and comment on what the benefits to life sciences would be if the UK would allow pensions to invest in private venture funds.

Dr. Berger, whose experience in biotech goes back decades, including founding and running ARIAD for 25 years, is taking over this company that was publicly launched at the beginning of 2024 and came with it a funding commitment of up to $500 million from large investors.

CEO Neil Miller walks us through the hypothesis of how toxic proteins created by neurodegenerative diseases enter and damage the mitochondria, and how the company's small molecule inhibitors are meant to block this. With these funds, the company can enter the clinic in Parkinson's in early 2026.

Co-Founder and CEO Eran Eshed describes the unmet need and how CHLOE Blast analyzes images from a time-laps incubator.

He describes how the idea is to cut down on control arm overlap used in numerous trials. If successful, it might free up space and resources to run faster and more efficient trials, and offer more participants a chance to be in experimental arms.

He shares what he believes the takeaways are from MAPLE-HCM, which studied aficamten vs a beta blocker in symptomatic obstructive hypertrophic cardiomyopathy patients. Plus, learnings from a competitor's data in non-obstructive HCM, and the status of the company's regulatory review.

Launched publicly today, and funded with $50M at this point, Corsera Health hopes to target those who are most at risk for atherosclerotic cardiovascular disease from an early age. The goal is to extend lives with an annual medicine by lowering LDL and blood pressure.

Trey Holterman describes how Tennr is trying to fix this process which relies on significant unstructured data and has traditional leads to onerous delays and unnecessary rejections.

Dr. Zou describes this work, which was published recently in Nature, and how the the AI scientists were able to do everything from debate internally to narrow down candidates from numerous possibilities.

He shares his take on today's data, which saw Viking's stock decline by over 40%, and Lilly's earlier data which also sparked a Wall Street disappointment. He describes whether he agrees with the reactions or not, and how the totality of the obesity market is shaping up.

Nucleate leaders describe what Nucleate has done for their education and career, and what they are looking forward to at this year's global summit in Boston.

Founder & CEO Ashoka Rejendra describes what the company offers, which is a not only a software package, but guidance on how to build and plan for the future. New entrepreneurs like those attending the Nucleate Summit are a natural prospect.

In this inaugural episode of Biotech Direct, BiotechTV's new show that will share the biotech industry's perspective on policy and regulatory news, Kendalle Burlin O'Connell and Daphne Zohar discuss the strategic importance of biotech to the United States, share their thoughts on new FDA initiatives, and brainstorm ways to raise public awareness of the importance of science.

Dr. Zocca describes the results of the trial, which showed a 19.4 months vs. 11.0 months mPFS benefit versus pembro alone, but narrowly missed statistical significance. She shares her take on the totality of the data and discusses the road ahead, including a Q3 meeting the company will have with FDA.

Warner Biddle describes the trajectory of the field, and how neuro-autoimmune conditions have emerged as Kyverna's most advanced programs. We discuss Stiff Person Syndrome, myasthenia gravis, MS and more.

Co-Founder & CEO Jim Martineau walks us through the platform and describes the importance of being cell type specific. The company utilized a combination of AI and high-throughput chemistry in the wet lab.

Dr. Rosenthal describes the unmet need in frontotemporal dementia and mechanism of action of latozinemab. He covers the trial design and explains why a new co-primary endpoint was recently added to the statistical plan. Plus, developing a similar medicine for early stage Alzheimer's, and how Alector is trying to get therapies across the blood-brain barrier more efficiently.

Founder & CEO Yujiro Hata describes the idea behind precision medicine and synthetic lethality. We discuss the company's pipeline assets Darovasertib, a DLL3 ADC, MAT2A, and more.